Press Releases

The deal, worth several billion dollars, is a future-looking model of technology-enabled target and drug discovery SALT LAKE CITY, Dec. 7, 2021 / PRNewswire / --  Recursion  (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug

Use of latest Recursion inference technologies to expand exploration of fibrosis and may extend the collaboration to more than a dozen programs in total Recursion's powerful inferential search capabilities leverage more than 100 million prior experiments conducted in Recursion's automated

Appointments will support continued expansion in neuroscience and acceleration of inferential search capabilities Tim Ahfeldt, Ph.D., Irit Rappley, Ph.D. and Glenn Morrison, Ph.D. to bolster neuroscience research and clinical development SALT LAKE CITY, Nov.

- Received Fast Track Designation for REC-2282, a potential treatment for NF2 meningiomas, and expect to enroll the first patient in a Phase 2/3 trial in early 2022 - Advanced REC-994, a potential treatment for CCM, and now expect to enroll the first patient in a phase 2 trial in early 2022 -

SALT LAKE CITY, Oct. 7, 2021 / PRNewswire / --  Recursion  (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that the U.S.

OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the closing of its previously-announced upsized initial public

SALT LAKE CITY, Sept. 29, 2021 / PRNewswire / --  Recursion  (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that the U.S.

Christensen to lead Recursion's Toronto office, opening in 2021 SALT LAKE CITY, Aug. 16, 2021 / PRNewswire / -- Recursion, a digital biology company industrializing drug discovery, today announced the appointment of Jordan Christensen as its Vice President of Engineering.

- Expanded the total number of research and development programs from 37 to 48 - Announced first internally-developed NCE is advancing to IND-enabling studies - Planning to expand operations to Canada, with Toronto serving as a multidisciplinary hub - Formed Therapeutics Advisory Board chaired by

Therapeutics Advisory Board to help guide Recursion's growing clinical pipeline through development SALT LAKE CITY, July 13, 2021 / PRNewswire / --  Recursion  (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry,